Literature DB >> 9245986

Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia.

C L Shovlin1, J M Hughes, J Scott, C E Seidman, J G Seidman.   

Abstract

To identify mutations that cause hereditary hemorrhagic telangiectasia (HHT, or Rendu-Osler-Weber syndrome), clinical evaluations and genetic studies were performed on 32 families. Linkage studies in four of eight families indicated an endoglin (ENG) gene mutation. ENG sequences of affected members of the four linked families and probands from the 24 small families were screened for mutations, by Southern blot analyses and by cycle sequencing of PCR-amplified DNA. Seven novel mutations were identified in eight families. Two mutations (a termination codon in exon 4 and a large genomic deletion extending 3' of intron 8) did not produce a stable ENG transcript in lymphocytes. Five other mutations (two donor splice-site mutations and three deletions) produce altered mRNAs that are predicted to encode markedly truncated ENG proteins. Mutations in other families are predicted to lie in ENG-regulatory regions or in one of the additional genes that may cause HHT. These data suggest that the molecular mechanism by which ENG mutations cause HHT is haploinsufficiency. Furthermore, because the clinical manifestation of disease in these eight families was similar, we hypothesize that phenotypic variation of HHT is not related to a particular ENG mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9245986      PMCID: PMC1715873          DOI: 10.1086/513906

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  32 in total

1.  Streamlined procedures for screening a P1 library.

Authors:  C L Shovlin
Journal:  Biotechniques       Date:  1996-09       Impact factor: 1.993

Review 2.  Hereditary hemorrhagic telangiectasia.

Authors:  A E Guttmacher; D A Marchuk; R I White
Journal:  N Engl J Med       Date:  1995-10-05       Impact factor: 91.245

Review 3.  Inherited diseases of the vasculature.

Authors:  C L Shovlin; J Scott
Journal:  Annu Rev Physiol       Date:  1996       Impact factor: 19.318

4.  Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.

Authors:  D W Johnson; J N Berg; M A Baldwin; C J Gallione; I Marondel; S J Yoon; T T Stenzel; M Speer; M A Pericak-Vance; A Diamond; A E Guttmacher; C E Jackson; L Attisano; R Kucherlapati; M E Porteous; D A Marchuk
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

5.  Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1.

Authors:  K A McAllister; K M Grogg; D W Johnson; C J Gallione; M A Baldwin; C E Jackson; E A Helmbold; D S Markel; W C McKinnon; J Murrell
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

6.  Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells.

Authors:  H Zhang; A R Shaw; A Mak; M Letarte
Journal:  J Immunol       Date:  1996-01-15       Impact factor: 5.422

7.  Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function.

Authors:  K A McAllister; M A Baldwin; A K Thukkani; C J Gallione; J N Berg; M E Porteous; A E Guttmacher; D A Marchuk
Journal:  Hum Mol Genet       Date:  1995-10       Impact factor: 6.150

8.  Medical complications of pregnancy in hereditary haemorrhagic telangiectasia.

Authors:  C L Shovlin; A R Winstock; A M Peters; J E Jackson; J M Hughes
Journal:  QJM       Date:  1995-12

9.  Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction.

Authors:  V Kaartinen; J W Voncken; C Shuler; D Warburton; D Bu; N Heisterkamp; J Groffen
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

10.  Endoglin modulates cellular responses to TGF-beta 1.

Authors:  P Lastres; A Letamendía; H Zhang; C Rius; N Almendro; U Raab; L A López; C Langa; A Fabra; M Letarte; C Bernabéu
Journal:  J Cell Biol       Date:  1996-06       Impact factor: 10.539

View more
  35 in total

Review 1.  Supermodels and disease: insights from the HHT mice.

Authors:  C L Shovlin
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 3.  New insights into the pathogenesis and treatment of primary pulmonary hypertension.

Authors:  N Rudarakanchana; R C Trembath; N W Morrell
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 4.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

5.  "Mistakes happen": somatic mutation and disease.

Authors:  F Qian; G G Germino
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

6.  Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia.

Authors:  F S Govani; A Giess; I G Mollet; M E Begbie; M D Jones; L Game; C L Shovlin
Journal:  Mol Syndromol       Date:  2013-04-11

7.  Three novel mutations in the activin receptor-like kinase 1 (ALK-1) gene in hereditary hemorrhagic telangiectasia type 2 in Brazilian patients.

Authors:  A M Assis; F F Costa; V R Arruda; J M Annichino-Bizzacchi; C S Bertuzzo
Journal:  J Hum Genet       Date:  2007-01-12       Impact factor: 3.172

8.  Expression of normal and truncated forms of human endoglin.

Authors:  U Raab; B Velasco; P Lastres; A Letamendía; C Calés; C Langa; E Tapia; J P López-Bote; E Páez; C Bernabéu
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

Review 9.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

Review 10.  The TGF-beta paradox in human cancer: an update.

Authors:  Maozhen Tian; William P Schiemann
Journal:  Future Oncol       Date:  2009-03       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.